1Michallet M, Tanguy ML, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle(SFGM). Br J Haematol,2000,108:400-407.
2Blau IW, Basara N, Bischoff M, et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Translant,2000,25:41-45.
3Byrne JL,Musuka C,Davy B, et al. Successful engraftment of a second transplant using non-myeloablative conditioning as treatment for graft failure following unrelated donor BMT. Bone Marrow Transplant. 2001, 27:547-549.
4Schlegel PG, Eyrich M, Bader P, et al. OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol, 2000,111:668-673.
5Naglet A, Or R,Naparsek E,et al. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol, 2000, 28 :1096-1104 .
6Silverman MM, Lee CK, Hohl R, et al. Second allogeneic stem cell transplantation for graft failure using an anti-thymocyte globulin(ATG)-Based regimen. Hematology. Am Society Hematology(abstract), 2001, 186a.
7Kroger N, Zabelina T, Kroger W, et al. Comparison of conditioning with or without anti-thymoeyte globulin (ATG)in allogeneic stem cell transplantation from related donors in patients with good risk myeloid leukemias. Hematology. Am Society Hematology (abstract) ,2001, 418a.
8Dey BR, Mcafee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-vs-host disease and anti-tumor response in patients with advanced hematologic malignancies treated with noumyeloablative conditioning and allogeneic stem cell transplantation. Hematology. Am Society Hematology ( abstract) ,2001, 417a.
